NCT06595563 2026-02-19
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06551116 2025-09-05
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
Recruiting
NCT03417544 2025-04-02
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting